Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURPASS-CVOT: tirzepatide versus dulaglutide for cardiovascular outcomes in type 2 diabetes
NL-OMON59410Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial in type 2 diabetes mellitus (T2DM) comparing Tirzepatide + standard of care with Dulaglutide + standard of care (2 arms). Primary endpoints: Time to first occurrence of major adverse cardiovascular event (MACE-3) and Time to first occurrence of a component event of MACE-3. Started Sep 2020; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON59410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59410.